Literature DB >> 17409347

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.

Deborah L White, Verity A Saunders, Steven R Quinn, Paul W Manley, Timothy P Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17409347     DOI： 10.1182/blood-2006-11-058032

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

2.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

Review 3.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition.

Authors:  Karmen Stankov; Suncica Stankov; Stevan Popović
Journal:  Med Oncol       Date:  2008-12-03       Impact factor: 3.064

5.  Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Onco Targets Ther       Date:  2008-10-01       Impact factor: 4.147

Review 6.  Nilotinib: a novel, selective tyrosine kinase inhibitor.

Authors:  Jean-Yves Blay; Margaret von Mehren
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

7.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12

8.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.

Authors:  C Hegedus; C Ozvegy-Laczka; A Apáti; M Magócsi; K Német; L Orfi; G Kéri; M Katona; Z Takáts; A Váradi; G Szakács; B Sarkadi
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 9.  The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Authors:  Taira Maekawa; Eishi Ashihara; Shinya Kimura
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.850

10.  A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Authors:  George D Demetri; Paolo G Casali; Jean-Yves Blay; Margaret von Mehren; Jeffrey A Morgan; Rossella Bertulli; Isabelle Ray-Coquard; Philippe Cassier; Monica Davey; Hossein Borghaei; Daniel Pink; Maria Debiec-Rychter; Wing Cheung; Stuart M Bailey; Maria Luisa Veronese; Annette Reichardt; Elena Fumagalli; Peter Reichardt
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.